An integrated genomic and metabolomic approach for defining survival time in adult oligodendrogliomas patients.
Fiche publication
Date publication
avril 2019
Journal
Metabolomics : Official journal of the Metabolomic Society
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHENARD Marie-Pierre, Dr DALI-YOUCEF Nassim, Pr ENTZ-WERLE Natacha, Pr NAMER Izzie-Jacques, Pr NOEL Georges, Dr SCHOTT Roland, Dr LHERMITTE Benoît, Pr PROUST François
Tous les auteurs :
Bund C, Guergova-Kuras M, Cicek AE, Moussallieh FM, Dali-Youcef N, Piotto M, Schneider P, Heller R, Entz-Werle N, Lhermitte B, Chenard MP, Schott R, Proust F, Noël G, Namer IJ
Lien Pubmed
Résumé
The identification of frequent acquired mutations shows that patients with oligodendrogliomas have divergent biology with differing prognoses regardless of histological classification. A better understanding of molecular features as well as their metabolic pathways is essential.
Mots clés
HRMAS-NMR spectroscopy, IDH, Metabolomics, Oligodendroglioma, Overall survival, PTEN
Référence
Metabolomics. 2019 Apr 29;15(5):69